Three Pathways have emerged in Innovative Access Agreements
The days of simply determining the market demand for a new drug as a function…
CertaraJune 11, 2021
Outcomes Based Agreements
The days of simply determining the market demand for a new drug as a function…
CertaraJune 11, 2021
De-risk your program with evidence-based secondary pharmacology insights
Safety issues account for about a quarter of the attrition in drug projects and can…
CertaraMay 28, 2021
Stakeholder perspectives: current and potential benefits
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
CertaraMay 26, 2021
Strengths and opportunities for HTAs and market access in Europe through case studies
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
CertaraMay 26, 2021
Similarities and differences between SNDS and other claim databases
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
CertaraMay 25, 2021
Using Authoring Templates to Write the Right Way
Creating submission-ready regulatory documents that are consistent in presentation, appropriate in content, and formatted to…
CertaraMay 25, 2021
Overview of SNDS and the key working practices to access the database and ongoing SNDS developments
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
CertaraMay 25, 2021
PBPK modeling approaches to assess risks associated with bioequivalence in drug development
In this webinar, Dr. Ioannis Loisios-Konstantinidis from Novartis, Switzerland discussed: Opportunities and challenges in conducting…
CertaraMay 19, 2021
Evidence generation in Europe- How valuable is the French National administrative health data (SNDS)
Evidence generation in Europe- How valuable is the French National administrative health data (SNDS)
Watch this presentation to learn • Overview of the SNDS and the key working practices…
CertaraMay 7, 2021
